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Abstract Ipilimumab, a cytotoxic T-lymphocyte antigen-
4 (CTLA-4) binding agent, has proven to be an effective
monotherapy for metastatic melanoma and has shown
antitumor activity in trials when administered with other
therapeutic agents. We hypothesized that the combination
of ipilimumab with chemotherapeutic agents, such as
ixabepilone, paclitaxel, etoposide, and gemcitabine, may
produce therapeutic synergy based on distinct but com-
plementary mechanisms of action for each drug and unique
cellular targets. This concept was investigated using a
mouse homolog of ipilimumab in preclinical murine tumor
models, including SA1N fibrosarcoma, EMT-6 mammary
carcinoma, M109 lung carcinoma, and CT-26 colon car-
cinoma. Results of CTLA-4 blockade in combination with
one of various chemotherapeutic agents demonstrate that
synergy occurs in settings where either agent alone was not
effective in inducing tumor regression. Furthermore, when
combined with CTLA-4 blockade, ixabepilone, etoposide,
and gemcitabine elicited prolonged antitumor effects in
some murine models with induction of a memory immune
response. Future investigations are warranted to determine
which specific chemo-immunotherapy combinations, if
any, will produce synergistic antitumor effects in the
clinical setting.
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Introduction
A complex and multifaceted interplay exists between the
immune system and cancer. Innate and adaptive immune
responses function to protect the host by attempting to
mediate rejection of the tumor, and conversely, the
immune system can also facilitate tumor progression by
secreting factors that support tumor growth and immune
escape, suppressing effective antitumor immunity. Fur-
thermore, during cancer progression, tumor cells can
develop multiple strategies to evade immune detection
and destruction [1, 2]; thus, agents that modulate
immune function are attractive therapeutic options to
generate and expand robust and effective antitumor
immune responses.
A vastly improved understanding of the mechanisms
and pathways that govern immune regulation has led to the
evaluation of novel therapeutic approaches targeting spe-
cific immune receptors/ligands within these pathways.
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is one such
receptor, and its role as a key negative regulator of T-cell
responses gives it the potential as a target for therapy in
multiple cancer types [3, 4].
One of the key events in the initiation of adaptive
immunity is the antigen-specific activation of naı¨ve T cells,
a process which is controlled by a precise balance of
stimulatory and inhibitory regulatory signals. Multiple
signals are required for effective T-cell activation [5],
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which is initiated by the engagement of the major histo-
compatibility antigen complex. After activation, CTLA-4,
a member of the immunoglobulin family and a homolog of
CD28, is expressed on the surface of T cells [6]. CTLA-4,
which has a higher affinity for binding B7 molecules than
does CD28, curtails T-cell activation and proliferation by
various mechanisms, including competitive inhibition of
CD28, delocalization of protein kinase C-theta and CAR-
MA1 from the immune synapse, transendocytosis of B7,
and modulation of regulatory T-cell (Treg) function [7–15].
Preclinical investigations in in vivo systems have con-
firmed the key role of CTLA-4 in immune regulation and
immunotherapy, demonstrated by the phenotype of CTLA-
4 knockout mice, which develop a lethal lymphoprolifer-
ative phenotype at a young age [16, 17]. Moreover, anti-
CTLA-4 monoclonal antibody (mAb) therapy in preclinical
cancer models produced antitumor activity, both as mono-
therapy and in combination with other therapeutic modalities
[3, 18–21], providing the rationale for clinical development of
human monoclonal antibodies that target CTLA-4.
Two fully human mAbs that bind CTLA-4, treme-
limumab (CP-675,206, Pfizer, New York, NY) and ipi-
limumab [22] (YervoyTM, Bristol-Myers Squibb,
Princeton, NJ), have been in clinical development over the
past decade [23, 24], and both agents have shown activity
in inducing tumor regression in clinical studies [25, 26].
Notably, ipilimumab has been approved in over 40 coun-
tries at a dose of 3 mg/kg for the treatment of unresectable
or metastatic melanoma, following the results of a phase III
study in advanced melanoma, in which ipilimumab
improved the overall survival relative to patients given
melanoma vaccine glycoprotein 100 monotherapy, with a
side-effect profile that was inflammatory in nature, con-
sistent with the agent’s immune-based mechanism of
action [24]. Ipilimumab also demonstrated improved sur-
vival and tolerability when administered with dacarbazine,
a chemotherapeutic agent, in a phase III trial in chemo-
therapy-naı¨ve patients with metastatic melanoma [27].
Chemo-immunotherapy is a novel approach for the
treatment of cancer that combines drugs that directly kill
tumor cells with interventions that modulate host immune
responses to the tumor. Preclinical and clinical evidence
suggests that chemotherapy may induce or support immu-
nity against tumor cells by various mechanisms. Chemo-
therapy-induced cell death may generate tumor antigens to
be presented by APCs, creating a ‘‘polyvalent’’ tumor-cell
vaccine in situ. Additionally, cytotoxic treatments may
distort the tumor architecture, thus facilitating the pene-
tration of the immunotherapeutic agents and the expanded
immune population [28–30]. The mechanism by which a
given chemotherapy impacts the immune system may be
different from another chemotherapy agent. As such,
combining immunotherapeutic strategies with more
traditional therapies, such as chemotherapeutic agents,
vaccines, and radiotherapy, is of particular clinical interest
in the treatment of cancer, but it remains to be seen which
combinations will produce synergistic antitumor effects in
the clinic. In addition to the potential for synergy, com-
bining immunotherapy with chemotherapy has been pro-
posed as a mechanism to overcome chemotherapeutic
resistance, which is a critical barrier to effective treatment
in some tumor types [31].
In the presented studies, we describe preclinical evi-
dence of synergy between CTLA-4 blockade and chemo-
therapeutic agents in various murine tumor models of
fibrosarcoma and cancers of the mammary gland, lung, and
colon. The chemotherapeutic agents tested in the study,
including ixabepilone, paclitaxel, etoposide, and gemcita-
bine, exhibit distinct mechanisms for antitumor activity
and represent common therapeutic options. Although the
studies herein employed a single schedule of drugs used at
optimal dose (OD) and therefore are not designed for direct
extrapolation to human malignancies—the antitumor
effects observed in these preclinical models provide the
rationale for further clinical investigation of these and other




Eight- to 12-week-old female BALB/c (Harlan, Indianap-
olis, IN) and A/J mice (Jackson, Bar Harbor, MA, USA)
comprised each cohort of 8–12 mice. The mice received
food and water ad libitum and were maintained in a con-
trolled environment according to the Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC) International regulations. All animal studies
have been approved by the appropriate ethics committee
and have, therefore, been performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments.
Antibodies and chemotherapeutic agents
Since ipilimumab is specific to human CTLA-4, these
experiments utilized an anti-mouse CTLA-4 mAb (anti-
mCTLA-4 mAb) clone 4F10-UC10-11 at an OD of 20 mg/
kg unless otherwise noted. Clone 4F10-UC10-11 was
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Anti-mCTLA-4 mAb was
produced and purified by Bristol-Myers Squibb (Protein
Therapeutics Division, Hopewell, NJ, USA) and was cer-
tified to have \0.5 EU/mg endotoxin levels, [95 % purity,
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and\5 % high molecular weight species. Stock solutions of
anti-mCTLA-4 mAb were kept at -80 C and thawed at 4 C
prior to use. Polyclonal hamster IgG (Jackson ImmunoRe-
search, West Grove, PA, USA) was utilized as the control
antibody. Dosing solutions of anti-mCTLA-4 mAb and
hamster IgG control were prepared in sterile phosphate-buf-
fered saline (pH 7.0). Antibodies used for immunostaining of
tumor-draining lymph nodes (TDLN) were purchased from
BD Biosciences (San Jose, CA, USA).
Chemotherapeutic agents employed included ixa-
bepilone (8 mg/kg, Bristol-Myers Squibb, Princeton, NJ,
USA), paclitaxel (24 mg/kg, Fondazione Michelangelo,
Milan, Italy), etoposide (40 mg/kg, LC Laboratories,
Woburn, MA, USA), and gemcitabine (120 mg/kg, Eli
Lilly, Indianapolis, IN, USA). Of note, these agents were
chosen because they are broadly utilized clinically as
standards of care across a wide spectrum of solid tumors.
Anti-mCTLA-4 mAb, ixabepilone, paclitaxel, or gem-
citabine were given every 4 days for 3 doses by intraperi-
toneal injection. Etoposide was administered intravenously
every 7 days for 3 doses. All drugs were administered in an
optimal schedule and dose specific to each tumor model as
determined in the preliminary experiments (data not
shown). To help mitigate the potential for chemotherapy to
affect T-cell function or viability, anti-mCTLA-4 mAb was
given 1 day after chemotherapy dosing (unless otherwise
noted in tables or figure legends).
Tumor models
SA1N fibrosarcoma, EMT-6 mammary carcinoma, M109
lung carcinoma, and CT-26 colon carcinoma tumor lines
used in this study were maintained in vitro. Cell suspen-
sions were implanted in the subcutaneous space of the flank
of mice. In some studies, mice that showed complete tumor
regression after therapy were rechallenged with a lethal dose
of tumor cells to determine the level of immune protection.
Efficacy studies were performed with each of the tumor
models. Antibodies and chemotherapeutic agents were
administered at OD; dosing schedules and routes for admin-
istration are shown for each study in Table 1 or described in
figure legends. Each treatment regimen consisted of cohorts
containing 8–12 mice. Tumor size and body weights were
measured twice weekly. Tumor size (measured as mm3) was
calculated by multiplying the tumor length by the square of the
tumor width and then dividing by 2. Treatments were initiated
when subcutaneous tumors reached a median size between
125 and 225 mm3 (established model; SA1N fibrosarcoma
and CT-26 colon carcinoma models) or prior to detection
(initiation model; EMT-6 mammary carcinoma and M109
lung carcinoma models), depending on the model’s sensitivity
to chemotherapy. In the established model, antitumor activ-
ity, defined as percentage tumor growth inhibition, was
calculated with the formula %Tumor Growth Inhibition
%TGIð Þ ¼ 100  Tt=Toð Þ= Ct=Coð Þ½ =100  Ct=Coð Þ ,
where Tt = median tumor size of treated group at the end of
treatment, To = median tumor size of treated group at
treatment initiation, Ct = median tumor size of control
group at the end of treatment, and Co = median tumor size at
treatment initiation. Since there is no baseline for tumor
volume in the initiation model, and therefore %TGI cannot
be calculated, we reported the percentage of tumor-free mice
at the end of each experiment. The tumor response endpoint
was expressed as tumor growth delay (T–C value), calculated
as the difference in time (days) between the treated (T) and
control (C) groups for the tumor to reach a predetermined
target size. A delay in reaching target size by the treated
groups of [1 times tumor volume doubling time was con-
sidered an active result. In the intravenous M109 lung carci-
noma model, survival was the targeted endpoint. Therapeutic
synergy was defined as an antitumor effect in which the
combination of agents demonstrated significant superiority
(p \ 0.05) relative to the activity shown by each agent alone.
In vivo cytotoxic cell assay
To examine in vivo cytotoxicity, mice bearing subcutane-
ous CT-26 colon tumors were treated with anti-mCTLA-4
mAb and each chemotherapeutic agent (individually or in
combination) as described. Two and 7 days after the final
treatment, mice (n = 5/group) were injected with car-
boxyfluorescein diacetate succinimidyl ester (CFSE)-
labeled syngeneic splenocytes pulsed with CT-26-specific
peptides (peptide AH-1, (H) SPSYVYHQF (OH), Sigma
Genosys; 2.5 lM CFSE) or left unpulsed as a control
(0.25 lM CFSE). Eighteen hours later, mice were eutha-
nized, spleens were removed, and splenocytes were iso-
lated and resuspended in phosphate-buffered saline (PBS).
Fluorescence of the cell suspensions was measured by flow
cytometry, and cytolytic activity was determined by mea-
suring the ratio of CFSE-labeled cells (CFSE high =
peptide pulsed, CFSE low = not pulsed).
Immunophenotyping of TDLN
To analyze the composition of TDLN in the CT-26 colon
carcinoma and M109 lung carcinoma tumor models,
TDLN were collected and cell suspensions were prepared
with a hand-held homogenizer. Cells were counted and
diluted into staining buffer (PBS, pH 7.0 plus 1 % fetal
calf serum and 0.1 % sodium azide) at a concentration of
1 9 107cells/mL. Cells were stained with fluorescent-labeled
antibodies for 45 min on ice, followed by two washes in
staining buffer. Cells were fixed in 0.1 % formaldehyde and
then subjected to flow cytometry analyses.
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Table 1 Antitumor activity of CTLA-4 blockade in combination with chemotherapies in tumor models








% CR or % tumor-
free mice (# per
total mice)
Best combination effect
Ixabepilone or paclitaxel in combination with anti-mCTLA-4 mAb
SA1N fibrosarcoma
(SC, A/J mice)a,b
CTLA-4 mAb Day 12, 16, 20 79 7 25
(2/8)
Ixa Day 11, 15, 19 83 7 0
(0/8)
Ixa ? CTLA-4 mAb Day 11, 15, 19




CTLA-4 mAb Day 11, 15, 19 79 7 25
(2/8)
Pac Day 10, 14, 18 0 0 0
(0/8)
Pac ? CTLA-4 mAb Day 10, 14, 18






CTLA-4 mAb Day 4, 8, 12 N/A 29 40
(4/10)
Ixa Day 3, 7, 11 N/A 19 20
(2/10)
Ixa ? CTLA-4 mAb Day 3, 7, 11




Pac Day 3, 7, 11 N/A 0 0
(0/10)
Pac ? CTLA-4 mAb Day 3, 7, 11
Day 4, 8, 12
N/A 37 40
(4/10)
M109 lung Ca (SC,
Balb/c mice)a
CTLA-4 mAb Days 4, 8, 12 N/A 4 0
(0/10)
Ixa Days 3, 7, 11 N/A [79 50
(5/10)
Ixa ? CTLA-4 mAb Days 3, 7, 11




rechallenge (75 % mice
with combination vs. 20 %
of mice treated with Ixa
alone)
Pac Days 3, 7, 11 N/A 7 0
(0/10)
Pac ? CTLA-4 mAb Days 3, 7, 11




CT-26 colon Ca (SC,
Balb/c mice)
CTLA-4 mAb Days 5, 9, 13 92 17 20
(2/10)
Ixa Days 4, 8, 12 26 0 0
(0/10)
Ixa ? CTLA-4 mAb Days 4, 8, 12




Pac Days 4, 8, 12 2 0 0
(0/10)
Pac ? CTLA-4 mAb Days 4, 8, 12
Days 5, 9, 13
103 [17 50
(5/10)
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Table 1 continued








% CR or % tumor-
free mice (# per
total mice)
Best combination effect
Etoposide in combination with anti-mCTLA-4 mAb
SA1N fibrosarcoma
(SC, A/J mice)
CTLA-4 mAbc Days 15, 18, 22 78 23 12.5
(1/8)
Etop Days 14, 21, 28 61 14 0
(0/8)
Etop ? CTLA-4c mAb Days 14, 21, 28




M109 lung Ca (IV,
Balb/c)
CTLA-4 mAb Days 5, 9, 13 N/A 1 N/A
Etopd Days 4, 11, 18 N/A 2.5 N/A
Etop ? CTLA-4 mAbd Days 4, 11, 18
Days 5, 9, 13
N/A 11.5 N/A Therapeutic synergy
CT-26 colon Ca (SC,
Balb/c)a
CTLA-4 mAb Days 9, 13, 17 22 0 0
(0/8)
Etopd Days 8, 15, 22 82 11 12.5
(1/8)
Etop ? CTLA-4 mAbd Days 8, 15, 22






Gemcitabine in combination with anti-mCTLA-4 mAb
SA1N fibrosarcoma
(SC, A/J mice)a
CTLA-4 mAbc Days 15, 18, 22 78 23 12.5
(1/8)
Gem Days 14, 18, 22 57 11 0
(0/8)
Gem ? CTLA-4 mAbc Days 14, 18, 22




M109 lung Ca (IV,
Balb/c mice)a
CTLA-4 mAb Days 5, 9, 13 N/A 3.5 N/A
Gem Days 4, 8, 12 N/A 11.5 N/A
Gem ? CTLA-4 mAb Days 4, 8, 12
Days 5, 9, 13
N/A 36.5 N/A Therapeutic synergy
CT-26 colon Ca (SC,
Balb/c mice)a
CTLA-4 mAb Days 9, 13, 17 22 0 0
(0/8)
Gem Days 8, 12, 16 85 11 25
(2/8)
Gem ? CTLA-4 mAb Days 8, 12, 16





rechallenge vs. 2/2 for
Gem alone)
CTLA-4 mAb anti-mouse CTLA-4 monoclonal antibody, Ca carcinoma, CR complete regression of tumor, Etop etoposide, Gem gemcitabine, Ixa ixabepilone, N/
A not applicable, SC subcutaneous, T–C number of days for treated group to reach target size—number of days for control group to reach target size, %TGI %
tumor growth inhibition calculated on the last measurement for control group, Tx treatment
a Representative of two independent studies
b One CR, which was non-treatment related, was observed in the control group in the SA1N tumor model
c Anti-mCTLA-4 mAb was administered at a dose of 10 mg/kg
d Etoposide was administered at a dose of 50 mg/kg
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Results
Antitumor activity of CTLA-4 blockade in combination
with microtubule-stabilizing agents, ixabepilone
and paclitaxel
In the SA1N fibrosarcoma model, use of ixabepilone in
combination with anti-mCTLA-4 mAb demonstrated ther-
apeutic synergy, yielding 112 % TGI, with 71.4 % (n = 5/7)
of the animals displaying complete tumor regression
(Table 1; Fig. 1a). Although paclitaxel monotherapy had
no therapeutic effect, addition of anti-mCTLA-4 mAb to
paclitaxel treatment yielded complete responses in 87.5 %
(n = 7/8) of the animals in the SA1N fibrosarcoma model
(Table 1; Fig. 1a) [32]. Both combination regimens
enhanced the antitumor effect of each monotherapy and
significantly delayed tumor growth to target size, resulting
in therapeutic synergy.
In the EMT-6 mammary carcinoma mouse model, the
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Fig. 1 Therapeutic synergy observed with CTLA-4 blockade in
combination with ixabepilone and paclitaxel in tumor models. In the
SA1N fibrosarcoma model (a), combination of anti-mCTLA-4 mAb
with either ixabepilone or paclitaxel resulted in therapeutic synergy,
with the majority of mice displaying substantially delayed tumor
growth over time. In the EMT-6 mammary carcinoma model (b),
combination of anti-mCTLA-4 mAb with ixabepilone yielded syner-
gistic effects over time, resulting in complete regression of tumors on
Day 18; anti-mCTLA-4 mAb paired with paclitaxel improved
antitumor activity without achieving a synergistic effect. Anti-
mCTLA-4 mAb in combination with ixabepilone expanded T
lymphocytes with cytolytic function by Day 19 (CD8?CD107?),
supporting synergistic efficacy in the EMT-6 mammary carcinoma
model (c, d). In the M109 lung carcinoma model (e), tumor-free mice
previously treated with ixabepilone monotherapy or in combination
with anti-mCTLA-4 mAb were rechallenged on Day 95 with live
tumor cells. The majority of mice (75 %) treated with the combina-
tion of anti-mCTLA-4 mAb and ixabepilone rejected the tumor
rechallenge, suggestive of a memory immune response. In the CT-26
colon carcinoma model (f), treatment of mice with anti-mCTLA-4
mAb and either ixabepilone or paclitaxel resulted in synergy between
CTLA-4 blockade and these chemotherapeutic agents. Expansion of
activated T cells (CD8?/CD69? and CD4?/CD69?) was observed
with anti-mCTLA-4 mAb alone and in combination with either
ixabepilone or paclitaxel (g, h)
1538 Cancer Immunol Immunother (2013) 62:1533–1545
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resulted in a synergistic therapeutic effect, inducing
complete regressions in 100 % (n = 10/10) of the treated
mice (Table 1; Fig. 1b). Paclitaxel alone did not show an
antitumor effect in the EMT-6 mammary carcinoma
mouse model (Table 1; Fig. 1b); furthermore, mice
treated with both paclitaxel and anti-mCTLA-4 mAb
blockade displayed improved antitumor activity without
achieving a synergistic effect (Table 1; Fig. 1b). Ixa-
bepilone in combination with anti-mCTLA-4 mAb
expanded T lymphocytes with cytolytic function by Day
19 (CD8?CD107?) (Fig. 1c, d) [32], an effect that was
not observed with paclitaxel in combination with anti-
mCTLA-4 mAb, consistent with the distinct therapeutic
outcome observed with these combinations.
Although treatment of M109 lung carcinoma mice with
ixabepilone alone produced effective inhibition of tumor
growth with 50 % of mice tumor-free following the initial
transplantation, therapy with either CTLA-4 blockade
alone or paclitaxel alone failed to demonstrate the antitumor
activity (Table 1; Fig. 1e). Combination of ixabepilone
or paclitaxel with anti-mCTLA-4 mAb resulted in 80 %
(8/10 mice) and 20 % (2/10 mice) tumor-free mice,
respectively, demonstrating enhanced antitumor activity
compared with either chemotherapeutic agent alone
(Table 1; Fig. 1e). To investigate whether the addition of
CTLA-4 blockade to ixabepilone modulated the immune
response to tumors, mice which were previously treated
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that were tumor-free were rechallenged on Day 95 with
M109 tumor cells subcutaneously. A cohort of untreated
mice served as controls, which had tumors that grew pro-
gressively (Fig. 1e). Conversely, the majority (75 %;
n = 6/8) of mice treated with the combination of ixa-
bepilone and anti-mCTLA-4 mAb rejected a subsequent
tumor rechallenge on Day 95, as compared with only 20 %
of mice treated with ixabepilone alone (Table 1; Fig. 1e).
Finally, in the CT-26 colon carcinoma model, the
combination of ixabepilone or paclitaxel with anti-
mCTLA-4 mAb resulted in effective tumor rejection, with
50–70 % (n = 5/10 and 7/10, respectively) of mice dis-
playing complete tumor regression (Table 1; Fig. 1f).
Additionally, expansion of activated T cells (CD8? and
CD4?) was observed with anti-mCTLA-4 mAb alone and
in combination with either ixabepilone or paclitaxel
(Fig. 1g, h) [32].
Antitumor activity of etoposide in combination
with anti-mCTLA-4 mAb
Therapeutic synergy was observed with etoposide and anti-
mCTLA-4 mAb in the SA1N fibrosarcoma, M109 lung
carcinoma, and CT-26 colon carcinoma murine models
(Table 1; Fig. 2). In the SA1N fibrosarcoma model, the
combination produced complete tumor regression in the
majority of mice (62.5 %; n = 5/8) (Table 1; Fig. 2a).
Additionally, significant prolongation of survival was
observed in the M109 lung metastasis model when this
combination was administered starting 4 days after intra-
venous tumor cell inoculation, which resulted in synergistic
effects (Table 1; Fig. 2b).
In the CT-26 colon carcinoma model, neither etoposide
nor anti-mCTLA-4 mAb alone were active at OD levels,
but their combination exhibited synergistic effects
(Table 1; Fig. 2c). Mice that reached complete regression
or naı¨ve mice were rechallenged with 1 9 106 CT-26
cells subcutaneously on Day 77 post-tumor cell implan-
tation. Although all naı¨ve mice developed tumors that
grew progressively, each of the mice treated with etopo-
side in combination with anti-mCTLA-4 mAb (n = 4)
rejected tumor rechallenge, leading the authors to inter-
pret that combination of CTLA-4 blockade plus etoposide
generated a memory immune response (Table 1). In vivo
cytotoxicity against a CT-26 tumor antigen showed a
































































































Fig. 2 Therapeutic synergy observed with CTLA-4 blockade in
combination with etoposide in tumor models. In the SA1N
fibrosarcoma model (a), M109 lung carcinoma model (b), and CT-
26 colon carcinoma model (c), therapeutic synergy was observed
with the administration of anti-mCTLA-4 mAb in combination with
etoposide relative to the treatment with either monotherapy. Efficacy
was evaluated either by tumor volume (a, c) or by survival
measurement (b)
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mCTLA-4 mAb without reaching statistical significance
(Fig. 3).
Antitumor activity of gemcitabine in combination
with anti-mCTLA-4 mAb
Co-administration of gemcitabine and anti-mCTLA-4 mAb
demonstrated synergy in the CT-26 colon carcinoma and
M109 lung carcinoma models, but not in the SA1N fibro-
sarcoma model (Table 1; Fig. 4). In the SA1N fibrosar-
coma model, anti-mCTLA-4 mAb alone and gemcitabine
alone showed modest activity but the combination of both
agents in this model did not result in therapeutic synergy
(Table 1; Fig. 4a). In the M109 lung metastasis tumor
model, OD levels of gemcitabine and anti-mCTLA-4 mAb
in combination resulted in therapeutic synergy with ani-
mals demonstrating increased survival, relative to animals
treated with either agent alone (Table 1; Fig. 4b). In the
CT-26 colon carcinoma model, this combination resulted in
synergistic effects, with 62.5 % (n = 5/8) of animals dis-
playing complete regressions (Table 1; Fig. 4c); however,
a lack of synergistic effects was observed in the CT-26
colon carcinoma model when a sequential dosing regimen
was explored, where 3 doses of gemcitabine were admin-
istered first (120 mg/kg) followed by administration of 3
doses of anti-mCTLA-4 mAb (20 mg/kg) (data not shown).
Similar to the experiments performed with etoposide
and ixabepilone as described previously, mice that had
reached complete regression in the CT-26 colon carcinoma
were rechallenged with a lethal dose of tumor cells
(1 9 106 CT-26 cells) on Day 77 post-tumor implantation
to determine the level of immune protection. Naı¨ve mice
were also included as a control in this assay, and as
expected, they developed tumors that grew increasingly
upon being challenged. However, all of the mice in the
gemcitabine treatment group (n = 2) and all of the mice
treated with gemcitabine plus anti-mCTLA-4 mAb (n = 5)
that initially displayed complete regressions rejected sub-
sequent tumor rechallenge (Table 1).
No significant enhancement of the cytotoxic activity
against a CT-26 tumor antigen was observed with the
combination of gemcitabine and anti-mCTLA-4 mAb
when compared with either treatment alone, as measured in
the in vivo cytotoxic cell assay (Fig. 3). However, the
combination treatment modulated the composition of the
TDLN cells. Specifically, gemcitabine in combination with
anti-mCTLA-4 mAb increased the levels of activated
(CD69?) CD4 and CD8 T cells while decreasing the
number of myeloid-derived suppressor cells (MDSC;
CD11b?GR1?) (Table 2).
Tolerability of the combination therapy
In each of the murine tumor models tested, addition of anti-
mCTLA-4 mAb following administration of each chemo-
therapeutic agent did not affect body weight loss above the
levels observed with the chemotherapeutic agents alone
(data not shown).
Discussion
The preclinical findings described offer evidence that




















































































































Fig. 3 In vivo cytotoxic activity toward a CT-26 tumor antigen. In
the CT-26 colon carcinoma mouse model, anti-mCTLA-4 mAb was
administered at a dose of 20 mg/kg on Days 8, 12, and 16. Etoposide
was administered at a dose of 50 mg/kg on Days 7, 14, and 21,
whereas gemcitabine was administered at a dose of 120 mg/kg on
Days 7, 11, and 15. In vivo cell kill was determined on Days 18 and
23 post-implant. One day prior to analysis, a 50:50 mixture of
peptide-pulsed ([H] SPSYVYHQF [OH], Sigma Genosys) and
peptide non-pulsed carboxyfluorescein diacetate succinimidyl ester
(CSFE)-labeled splenocytes from naive BALB/c donors were
adoptively transferred via IV tail injection into treated animals;
24 h later, spleens were removed and analyzed via flow cytometry to
determine the percent cell kill of peptide-pulsed cells. In vivo
cytotoxicity against a CT-26 tumor antigen showed a slight increase
in the CTLA-4 blockade and etoposide combination group without
reaching statistical significance versus anti-mCTLA-4 mAb alone. At
these time points, there were no significant enhancements of the
cytotoxic activity against a CT-26 tumor antigen with the combina-
tion of anti-mCTLA-4 mAb and gemcitabine when compared with
either treatment alone
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chemotherapeutic agents that exhibit different mechanisms
of action, including ixabepilone, paclitaxel, etoposide, and
gemcitabine, elicited synergistic antitumor activity in
murine tumor models when administered concurrently. In
data from experiments in multiple tumor models involving

































































































Fig. 4 Therapeutic synergy observed with CTLA-4 blockade in
combination with gemcitabine in tumor models. In the SA1N
fibrosarcoma model (a), the combination of anti-mCTLA-4 mAb
with gemcitabine did not produce therapeutic synergy. In the M109
lung carcinoma model (b) and CT-26 colon carcinoma model (c),
therapeutic synergy was observed with administration of anti-
mCTLA-4 mAb in combination with gemcitabine relative to the
treatment of mice with either monotherapy
Table 2 Effect of CTLA-4 blockade and gemcitabine on immune cells in tumor-draining lymph nodes following 3 doses
Immune cell populations Control CTLA-4 mAb Gem Gem ? CTLA-4 mAb




% CD4? CD69? (activated CD4? cells) 8.7 ± 1.0 14.2 ± 0.9
(p \ 0.01)
9.5 ± 1.1 11.7 ± 0.5
(p \ 0.01)
% CD8? 19.3 ± 0.5 18.6 ± 2.4 21.7 ± 2.1 20.5 ± 1.0
% CD8? CD69? (activated CD8? cells) 4.2 ± 0.5 4.9 ± 0.2
(p \ 0.05)
3.8 ± 0.4 4.8 ± 0.4
(p \ 0.05)





% CD11b?Gr1? (myeloid-derived suppressor cells) 2.24 ± 0.5 2.45 ± 0.7 2.45 ± 0.8 1.45 ± 0.3
(p \ 0.05)
CTLA-4 mAb anti-mouse CTLA-4 monoclonal antibody, Gem gemcitabine, p p value versus control
In the CT-26 colon carcinoma model, gemcitabine was administered at a dose of 120 mg/kg on Days 7, 11, and 15, and anti-mCTLA-4 mAb was
administered at a dose of 20 mg/kg on Days 8, 12, and 16 post-tumor implant. On Day 17, 4 mice/group were sacrificed and tumor-draining
lymph nodes were collected and processed for immunophenotypic analyses. Data are expressed as mean % ± standard deviation
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agents, synergy was observed in settings where blockade
with anti-mCTLA-4 mAb alone was ineffective or in
models where the chemotherapeutic agent alone did not
induce tumor regression.
In tumor models where CTLA-4 blockade demonstrated
modest antitumor effects, such as in the SA1N fibrosar-
coma, EMT-6 mammary carcinoma, and CT-26 colon
carcinoma models, synergy was observed in combination
with chemotherapy, independent of the intrinsic potency of
the chemotherapeutic agent, which suggests that the che-
motherapeutic agents tested in this study may potentiate the
effect of anti-mCTLA-4 mAb in settings where CTLA-4
blockade may be efficacious. Conversely, synergy with
etoposide and gemcitabine was also observed in the M109
lung carcinoma model in which CTLA-4 blockade was
inactive, even when these chemotherapeutic agents dem-
onstrated modest effect as monotherapy. Nevertheless, the
limitations of the present study preclude a definitive con-
clusion regarding the contributing factors responsible for
the superior antitumor effect elicited by the combination
treatments.
Although in some models we observed synergy and
expansion of CD8?CD107? T lymphocytes with CTLA-4
blockade in combination with ixabepilone, we did not see
such an effect with paclitaxel. Because the mechanisms of
action for ixabepilone and paclitaxel virtually overlap, the
observed differences in efficacy (SA1N fibrosarcoma,
EMT-6 mammary carcinoma, and M109 lung carcinoma
models) and cytotoxic T cells (M109 lung carcinoma
model) may be attributed to the inherent potency of ixa-
bepilone in these models. On the other hand, while both
ixabepilone and paclitaxel were inactive in the CT-26
colon carcinoma model, enhanced efficacy was observed in
combination with anti-mCTLA-4 mAb, suggesting that
perhaps minimum induction of tumor cell death was nec-
essary in this model to prime an immune response and
potentiate the effect of CTLA-4 blockade. However, a
direct immunomodulatory effect by these agents cannot be
eliminated [33–35].
In this study, treatment with anti-mCTLA-4 mAb
increased the frequency of activated CD4? and CD8? T
cells (CD69?), and this effect was not altered by the
addition of chemotherapy. Expansion of activated T cells
has been reported in clinical trials in melanoma with ipi-
limumab [36], which has been proposed to be the result of
the pharmacodynamic activity of this compound. It was of
interest then to observe that the addition of chemotherapy
did not alter this effect in murine models, and, as such, it
could be used as a candidate biomarker to evaluate how a
combination partner may modulate this pharmacologic
effect of ipilimumab in clinical settings.
Of note, tolerability to the chemotherapeutic agent was
not altered with the addition of anti-mCTLA-4 mAb,
indicating that the particular chemo-immunotherapy com-
binations tested did not affect the safety profile of the
chemotherapeutic agent or produce overt toxicities in mice.
Since adverse events resulting from therapy with CTLA-4
blocking antibodies in murine models are not predictive of
adverse events in humans, definitive characterization of the
tolerability of the combinations awaits further testing in the
clinic.
Importantly, addition of anti-mCTLA-4 mAb to ixa-
bepilone, etoposide, or gemcitabine resulted in the gener-
ation of a memory immune response in various tumor
models, including the M109 lung carcinoma and CT-26
colon carcinoma models, as evidenced by the rejection of a
secondary tumor challenge. It is increasingly recognized
that chemotherapy may evoke an antitumor immune
response, and that effect may be responsible for their
efficacy in clinical settings [29]. However, chemotherapy
alone may not produce the desirable effect of inducing
immune memory, which may inhibit tumor relapse. Of
note, CTLA-4 blockade has been shown previously to
induce memory immune responses [32]. Our presented
combination studies showed that chemotherapy supported,
or at least did not blunt, the generation of a memory
immune response. Furthermore, even in settings where
chemotherapy yielded complete tumor regressions (e.g.,
ixabepilone in the M109 fibrosarcoma model), this effect
was not sufficient to promote antitumor immunity since
most of the mice that rejected tumor rechallenge also
received anti-mCTLA-4 mAb (Table 1).
The results reported here demonstrate synergy between
specific chemotherapeutic agents and CTLA-4 blockade in
tumor regression. This is further supported by a recent study
by Ariyan et al. [37] in which mice bearing a transplantable
prostate tumor (TRAMPC2) treated with gemcitabine plus
a-CTLA-4 experienced longer median survival
(\125 days) than mice treated with gemcitabine mono-
therapy (72 days, p \ 0.05). Furthermore, the study dem-
onstrated that prolonged survival was associated with an
accumulation of CD8 cells that are tumor-specific, whereas
depletion of CD8 cells reduced the efficacy of this treatment
[37]. A study by Lesterhuis et al. [38] demonstrated that a
concurrent schedule of gemcitabine in combination with
CTLA-4 blockade in two murine tumor models yields
synergistic effects resulting in the induction of a potent
antitumor immune response, which confirms our observa-
tions described in this manuscript. Of note, depletion
analyses performed by Lesterhuis et al. [38] demonstrated
that both CD4? and CD8? T cells are required for optimal
therapeutic effect. Lastly, Wu et al. [39] have shown that
CTLA-4 blockade in combination with cisplatin demon-
strated improved antitumor activity versus each agent alone
in a mouse model of mesothelioma. The combination
therapy resulted in increased tumor infiltration of T cells
Cancer Immunol Immunother (2013) 62:1533–1545 1543
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and enhanced production of cytokines associated with
cytotoxic T-cell function [39]. In the studies presented,
expansion of CD8 T cells with cytolytic phenotype or
function was observed with the combination of ixabepilone
and anti-mCTLA-4 mAb in the EMT-6 mammary tumor
model as well as with the pairing of etoposide and CTLA-4
blockade in the CT-26 colon carcinoma model. However,
the precise mechanisms associated with the synergistic
effects observed in the present studies were not fully
characterized, and mechanistic studies will be required to
identify the role of different cellular subsets in the genera-
tion of effective antitumor immunity.
In the clinic, ipilimumab has been evaluated in combi-
nation with dacarbazine in melanoma [27] or with paclit-
axel/carboplatin in melanoma and lung cancer [40–42].
These clinical studies were designed to compare the
activity of an ipilimumab-containing regimen to that of a
chemotherapy control [27, 40–42]. Data from these clinical
studies [27, 40–42] demonstrated improvement in overall
survival with the combination regimen versus dacarbazine
alone or improvement in immune-related progression-free
survival in combination with paclitaxel/carboplatin. How-
ever, it is difficult to compare the results of the experiments
presented in this article to these clinical studies since dif-
ferent chemotherapies and schedules were applied. Since
the effect of distinct chemotherapeutic agents on tumor cell
killing and/or immune function varies among agents, there
are a myriad of possibilities in terms of schedules, doses,
partnering agents, and tumor models that may be examined
in future studies.
Overall, the data presented illustrate how a dual
approach utilizing chemotherapy and anti-mCTLA-4 mAb
can enhance antitumor effects over either agent alone in
certain murine cancer models. It is important to note that
the optimal schedule and dose to produce such antitumor
effects in these murine models are not directly translatable
to studies in humans. Furthermore, the impact of individual
chemotherapies on the immune system and on their ability
to kill tumor cells vary from each other, and these differ-
ences may be important in guiding choice of agents when
combining chemotherapy with immunotherapy to optimize
clinical outcomes. The data herein support the validity of
combining chemotherapy with CTLA-4 blockade to
mediate tumor regression and suggest further clinical study
of these regimens for the treatment of cancer is warranted.
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